Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342563 · ClinicalTrials.gov registry record · Phase 2
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients
A Phase 2 study of Alcoholism, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 1
- Study location
NCT00342563 is a Phase 2 study of Alcoholism that has completed, run by Yale University. The registered enrollment target is 136 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00342563, a Phase 2 study of Alcoholism, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol consumption in smoking and non-smoking alcohol dependent patients. We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption than placebo. We further hypothesize that mecamylamine will be effective in reducing both alcohol consumption and smoking in a subset of alcoholics who also smoke.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG mecamylamine
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2004-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00342563
The ClinicalTrials.gov registry entry for NCT00342563 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (64% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00342563 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00342563 about?
NCT00342563 is a clinical study titled "Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients". The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol consumption in smoking and non-smoking alcohol dependent patients. We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption than placebo. We further hypothesize that mecam...
What is the current status of trial NCT00342563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2004-05. Estimated completion is 2015-07.
What conditions does trial NCT00342563 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT00342563?
The interventions under investigation include: Placebo (DRUG), mecamylamine (DRUG).
Who is sponsoring clinical trial NCT00342563?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00342563 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Ibudilast for Treating Alcohol Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Gabapentin Treatment of Alcohol Dependence
COMPLETED · Phase 2
-
A Study of LY2940094 in Participants With Alcohol Dependency
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.